Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y1NC
|
|||
| Former ID |
DIB016020
|
|||
| Drug Name |
CHS-828
|
|||
| Synonyms |
Cancer therapeutics, LEO Pharma; GMX-1778
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1/2 | [1] | |
| Company |
LEO Pharma A/S
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H22ClN5O
|
|||
| Canonical SMILES |
C1=CC(=CC=C1OCCCCCCN=C(NC#N)NC2=CC=NC=C2)Cl
|
|||
| InChI |
1S/C19H22ClN5O/c20-16-5-7-18(8-6-16)26-14-4-2-1-3-11-23-19(24-15-21)25-17-9-12-22-13-10-17/h5-10,12-13H,1-4,11,14H2,(H2,22,23,24,25)
|
|||
| InChIKey |
BOIPLTNGIAPDBY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 200484-11-3
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:95016
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nicotinamide phosphoribosyltransferase (NAMPT) | Target Info | Inhibitor | [1], [2] |
| BioCyc | NAD salvage | |||
| KEGG Pathway | Nicotinate and nicotinamide metabolism | |||
| Metabolic pathways | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| IL1 Signaling Pathway | ||||
| TCR Signaling Pathway | ||||
| Pathwhiz Pathway | Nicotinate and Nicotinamide Metabolism | |||
| Reactome | BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||
| WikiPathways | Adipogenesis | |||
| Metabolism of water-soluble vitamins and cofactors | ||||
| Circadian Clock | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804. | |||
| REF 2 | Structural basis for resistance to diverse classes of NAMPT inhibitors. PLoS One. 2014 Oct 6;9(10):e109366. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.